Table 2. Time to antiretroviral Therapy (ART) and viral loads at baseline and follow up visits after ART initiation in individuals with newly diagnosed acute, early or chronic HIV infection, and those who initiated integrase inhibitor versus protease inhibitor based ART regimen.

Characteristics and Time points	Number of individuals (n, %)	Time from Diagnosis to ART initiation (days, range)	Time from HIV care intake visit to ART initiation (days, range)	Baseline Viral load log10 RNA (median, range)	Week 4 Viral load log10 RNA (median, range)	Week 4 Virally suppressed (n, %)	Week 12 Viral load log10 RNA (median, range)	Week 12 Virally suppressed (n, %)	Week 24 Viral load log10 RNA (median, range)	Week 24 Virally suppressed (n, %)	Week 48 Viral load log10 RNA (median, range)	Week 48 Virally suppressed
Acute HIV infection	36 (42%)	14 (0–29)	10 (0–23)	5.74 (1.89–7.48)	2.46 (1.30–5.01)	7 (19%)	1.75 (1.30–4.15; n = 33)	16 (48%)	1.32 (1.30–2.26; n = 25)	20 (80%)	1.30 (1.09–4.98; n = 25)	22 (88%)
Early HIV infection	27 (31%)	13 (0–28)	8 (0–28)	4.65 (2.89–7.00)	1.92 (1.30–.67; n = 25)	10 (40%)	1.36 (1.30–2.69; n = 26)	15 (58%)	1.30 (1.30–3.91; n = 23)	21 (91%)	1.43 (1.30–4.59; n = 21)	19 (90%)
Chronic HIV infection	23 (27%)	9 (0–21)	7 (0–14)	4.54 (2.48–6.47)	1.85 (1.30–3.41; n = 22)	9 (41%)	1.30 (1.30–1.96; n = 20)	18 (90%)	1.30 (1.30–2.04; n = 18)	18 (82%)	1.30 (1.30–1.60; n = 14)	14 (100%)
Integrase inhibitor-based ART Regimen	56 (65%)	9 (0–29)	6 (0–28)	4.80 (1.89–7.00)	1.90 (1.30–3.78; n = 53)	20 (38%)	1.30 (1.30–2.85; n = 50)	38 (76%)	1.30 (1.30–3.91; n = 49)	43 (88%)	1.30 (1.09–4.98; n = 36)	33 (92%)
Protease inhibitor-based ART Regimen	30 (35%)	16 (0–22)	13 (0–21)	5.22 (2.89–7.48)	2.80 (1.30–5.02)	6 (20%)	2.11 (1.30–4.15; n = 29)	11 (21%)	1.68 (1.30–2.26; n = 21)	16 (76%)	1.68 (1.30–1.91; n = 24)	22 (92%)